Novo Nordisk shares fall 16% as new obesity drug trails Eli Lilly
Novo Nordisk shares fall 16% as new obesity drug trails Eli Lilly is drawing significant interest across the industry.
CagriSema achieved a 23% weight reduction over 84 weeks, but this was seen as disappointing and Novo has lost $400 billion in market value since a peak in 2024
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- How shirtless protest at AI summit puts Youth Congress back in spotlight
- Will your travel insurance cover flight delay or cancellation? Here's what you need to know amid Gulf airspace closures
- From OKCupid to community wedding: Jackie and Aimee's love story
- Will Thailand’s election be voided? Bar code blunder threatens to tear up results
Source: Original →